

**Amendments to the Specification:**

Please replace paragraph [00124], bridging pages 35 to 36, with the following amended paragraph:

The invention encompasses antibodies (preferably monoclonal antibodies) or fragments thereof that specifically bind FcγRIIB, preferably human FcγRIIB, more preferably native human FcγRIIB with a greater affinity than said antibodies or fragments thereof bind FcγRIIA, preferably human FcγRIIA, more preferably native human FcγRIIA. Preferably, the antibodies of the invention bind the extracellular domain of native human FcγRIIB. In certain embodiments, the antibodies or fragments thereof bind to FcγRIIB with an affinity greater than two-fold, four fold, 6 fold, 10 fold, 20 fold, 50 fold, 100 fold, 1000 fold,  $10^4$  fold,  $10^5$  fold,  $10^6$  fold,  $10^7$  fold, or  $10^8$  fold than said antibodies or fragments thereof bind FcγRIIA. In one particular embodiment, the antibody is a mouse monoclonal antibody produced by clone 2B6 or 3H7, having ATCC accession numbers PTA-4591 and PTA-4592, respectively. Hybridomas producing antibodies of the invention have been deposited with the American Type Culture Collection (10801 University Blvd., Manassas, VA. 20110-2209) on August 13, 2002 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned accession numbers PTA-4591 (for hybridoma producing 2B6) and PTA-4592 (for hybridoma producing 3H7), respectively and are incorporated herein by reference. In a specific embodiment, the invention encompasses an antibody with the heavy chain having the amino acid sequence of SEQ ID No 2 and the light chain having the amino acid sequence of SEQ ID No. 4. In a preferred embodiment, the antibodies of the invention are human or have been humanized, preferably a humanized version of the antibody produced by clone 3H7 or 2B6. In yet another preferred embodiment, the antibodies of the invention further do not bind Fc activation receptors, *e.g.*, FcγRIIA, FcγRIIB, *etc.* In one embodiment, the FcγRIIB-specific antibody in accordance with the invention is not the monoclonal antibody designated KB61, as disclosed in Pulford *et al.*, 1986 (*Immunology*, 57: 71-76) or the monoclonal antibody designated MAbII8D2 as disclosed in Weinrich *et al.*, 1996, (*Hybridoma*, 15(2):109-6). In a specific embodiment, the FcγRIIB-specific antibody of the invention does not bind to the same epitope and/or does not compete

with binding with the monoclonal antibody KB61 or II8D2. Preferably, the FcγRIIB-specific antibody of the invention does not bind the amino acid sequence SDPNFSI (SEQ ID NO:5) corresponding to positions 135-141 of FcγRIIb2 isoform.

Please replace paragraph [00125] at page 36 with the following amended paragraph:

The invention also encompasses other antibodies, preferably monoclonal antibodies or fragments thereof that specifically bind FcγRIIB, preferably human FcγRIIB, more preferably native human FcγRIIB, produced by clones including but not limited to 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, \_\_\_\_\_, \_\_\_\_\_, \_\_\_\_\_, \_\_\_\_\_, \_\_\_\_\_, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. Hybridomas producing the above-identified clones were deposited with the American Type Culture Collection (10801 University Blvd., Manassas, VA. 20110-2209) on \_\_\_\_\_, respectively May 7, 2004 and are incorporated herein by reference.

Please replace the table immediately following paragraph [00179] at page 58 with the following amended table:

<b>Plasmid</b>	<b>Receptor</b>	<b>N-ter</b>	<b>172-180</b>	<b>C-ter</b>
pMGX125	RIIb	IIb	KKFSRSDPN (SEQ ID NO:6)	APS-----SS (IIb) (SEQ ID NO:12)
pMGX126	RIIa/b	IIa	QKFSRLDPN (SEQ ID NO:7)	APS-----SS (IIb) (SEQ ID NO:12)
pMGX127		IIa	QKFSRLDPT (SEQ ID NO:8)	APS-----SS (IIb) (SEQ ID NO:12)
pMGX128		IIb	KKFSRLDPT (SEQ ID NO:9)	APS-----SS (IIb) (SEQ ID NO:12)
pMGX129		IIa	QKFSHLDPT (SEQ ID NO:10)	APS-----SS (IIb) (SEQ ID NO:12)
pMGX130		IIb	KKFSHLDPT (SEQ ID NO:11)	APS-----SS (IIb) (SEQ ID NO:12)
pMGX131		IIa	QKFSRLDPN (SEQ ID NO:7)	VPSMGSSS(IIa) (SEQ ID NO:13)
pMGX132		IIb	KKFSRSDPN (SEQ ID NO:6)	VPSMGSSS(IIa) (SEQ ID NO:13)
pMGX133	RIIa-131R	IIa	QKFSRLDPT (SEQ ID NO:8)	VPSMGSSS(IIa) (SEQ ID NO:13)
pMGX134	RIIa-131H	IIa	QKFSHLDPT (SEQ ID NO:10)	VPSMGSSS(IIa) (SEQ ID NO:13)
pMGX135		IIb	KKFSRLDPT (SEQ ID NO:9)	VPSMGSSS(IIa) (SEQ ID NO:13)
pMGX136		IIb	KKFSHLDPT (SEQ ID NO:11)	VPSMGSSS(IIa) (SEQ ID NO:13)